130 related articles for article (PubMed ID: 17455874)
1. Characteristics of metastasis as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Ku JH
Tumori; 2007; 93(1):68-74. PubMed ID: 17455874
[TBL] [Abstract][Full Text] [Related]
2. Sarcomatoid differentiation as a prognostic factor for immunotherapy in metastatic renal cell carcinoma.
Kwak C; Park YH; Jeong CW; Jeong H; Lee SE; Moon KC; Ku JH
J Surg Oncol; 2007 Mar; 95(4):317-23. PubMed ID: 17066434
[TBL] [Abstract][Full Text] [Related]
3. Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2005 Aug; 20(4):410-6. PubMed ID: 16114989
[TBL] [Abstract][Full Text] [Related]
4. No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?
Kwak C; Park YH; Jeong CW; Lee SE; Ku JH
Urol Oncol; 2007; 25(4):310-6. PubMed ID: 17628297
[TBL] [Abstract][Full Text] [Related]
5. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial.
Gore ME; Griffin CL; Hancock B; Patel PM; Pyle L; Aitchison M; James N; Oliver RT; Mardiak J; Hussain T; Sylvester R; Parmar MK; Royston P; Mulders PF
Lancet; 2010 Feb; 375(9715):641-8. PubMed ID: 20153039
[TBL] [Abstract][Full Text] [Related]
6. The role of adjuvant immunotherapy after radical nephrectomy and prognostic factors in pT3N0M0 renal cell carcinoma.
Jeon SH; Chang SG; Kim JI
Anticancer Res; 1999; 19(6C):5593-7. PubMed ID: 10697624
[TBL] [Abstract][Full Text] [Related]
7. Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials.
Leibovich BC; Han KR; Bui MH; Pantuck AJ; Dorey FJ; Figlin RA; Belldegrun A
Cancer; 2003 Dec; 98(12):2566-75. PubMed ID: 14669275
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
9. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
May M; Helke C; Bock M; Hoschke B
Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
[TBL] [Abstract][Full Text] [Related]
10. Age does not impair the efficacy of immunochemotherapy in patients with metastatic renal carcinoma.
Atzpodien J; Wandert T; Reitz M
Crit Rev Oncol Hematol; 2005 Sep; 55(3):193-9. PubMed ID: 16115777
[TBL] [Abstract][Full Text] [Related]
11. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
Pantuck AJ; Belldegrun AS; Figlin RA
N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
[No Abstract] [Full Text] [Related]
12. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
13. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen.
Henriksson R; Nilsson S; Colleen S; Wersäll P; Helsing M; Zimmerman R; Engman K
Br J Cancer; 1998 Apr; 77(8):1311-7. PubMed ID: 9579838
[TBL] [Abstract][Full Text] [Related]
14. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
15. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma.
van Herpen CM; De Mulder PH
Crit Rev Oncol Hematol; 2002 Mar; 41(3):327-34. PubMed ID: 11880208
[TBL] [Abstract][Full Text] [Related]
16. [Systemic immunotherapy of metastatic renal cell carcinoma and long-term outcome].
Brinkmann OA; Roigas J; Hertle L
Urologe A; 2002 May; 41(3):231-8. PubMed ID: 12132272
[TBL] [Abstract][Full Text] [Related]
17. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
18. Metastatic renal carcinoma comprehensive prognostic system.
Atzpodien J; Royston P; Wandert T; Reitz M;
Br J Cancer; 2003 Feb; 88(3):348-53. PubMed ID: 12569375
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma.
Hofmann HS; Neef H; Krohe K; Andreev P; Silber RE
Eur Urol; 2005 Jul; 48(1):77-81; discussion 81-2. PubMed ID: 15967255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
